Hepion net loss narrows to $810,791 in Q1 FY26; operating loss improves to $798,509

HEPION PHARMACEUTICALS INC

HEPION PHARMACEUTICALS INC

HEPA

0.00
  • Hepion Pharmaceuticals posted a narrower net loss of USD 810,791 for quarter ended March 31, 2026, versus USD 6,105,887 a year earlier.
  • Operating loss narrowed to USD 798,509 from USD 1,280,595, while interest expense eased to USD 2,129 from USD 24,811.
  • Research and development expense climbed to USD 70,000 from USD 22,235, primarily tied to Cirna licensing agreement.
  • General and administrative expense fell to USD 728,509 from USD 1,258,360, on lower legal and accounting fees, insurance, consulting and outside services, partly offset by higher severance.
  • Cash totaled USD 2.6 million at March 31, 2026; net cash from operating activities was USD 578,584, driven by a USD 1 million refund from previously inactive prepaid insurance policy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023136), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.